Group 1 - The core point of the news is that Yiming Biotech-B (01541) has seen a nearly 4% increase in stock price following the announcement of the acceptance of its clinical trial application for IMM0306S, a dual-target antibody drug for systemic lupus erythematosus (SLE) by the National Medical Products Administration (NMPA) [1] - The drug IMM0306S is a subcutaneous formulation developed based on Yiming Biotech's core product IMM0306, which is the world's first clinical-stage dual-target molecule targeting CD47 and CD20, developed using the "mAb-Trap" technology platform [1] - The acceptance of the clinical trial application marks a significant advancement in the company's innovative drug development in the field of autoimmune diseases [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Biotech presented data from a Phase I/II clinical study of IMM0306 combined with lenalidomide for relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% in patients who had previously failed at least one line of anti-CD20 monoclonal antibody treatment [2] - The safety profile of the combination therapy is manageable, with no risk of cytokine release syndrome reported, providing a promising new immunotherapy strategy for this currently incurable disease with limited treatment options after relapse [2]

Group 1 - The core viewpoint of the news is that Yiming Biotech-B (01541) has made significant progress in the development of innovative drugs for autoimmune diseases, with the acceptance of the clinical trial application for its dual-target antibody IMM0306S by the National Medical Products Administration (NMPA) [1] - IMM0306S is a subcutaneous formulation developed based on Yiming Biotech's core product, IMM0306, which is the world's first clinical-stage dual-target specific molecule targeting CD47 and CD20, developed using the company's "mAb-Trap" technology platform [1] - The stock price of Yiming Biotech-B increased nearly 4%, with a current price of 6.23 HKD and a trading volume of 3.1192 million HKD [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Biotech presented data from a Phase I/II clinical study of IMM0306 combined with lenalidomide for the treatment of relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% in patients who had failed at least one line of anti-CD20 monoclonal antibody treatment [2] - The safety profile of the combination therapy is manageable, with no risk of cytokine storm, providing a promising new immunotherapy strategy for this currently incurable disease with limited treatment options after relapse [2]

Group 1 - The core viewpoint of the news is that Yiming Anke-B (01541) has made significant progress in the development of innovative drugs for autoimmune diseases, with the acceptance of the clinical trial application for IMM0306S by the National Medical Products Administration (NMPA) [1] - IMM0306S is a subcutaneous formulation of the bispecific antibody targeting CD47 and CD20, developed based on the company's core product IMM0306, which is the world's first CD47xCD20 bispecific molecule to enter clinical stages [1] - The stock price of Yiming Anke-B increased by nearly 4%, with a trading volume of 3.1192 million Hong Kong dollars, reflecting positive market sentiment following the announcement [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Anke presented data from the I/II clinical study of IMM0306 combined with lenalidomide for relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% [2] - The safety profile of the combination therapy was reported to be manageable, with no risk of cytokine release syndrome, indicating a promising new immunotherapy strategy for a currently incurable disease with limited treatment options [2] - The ongoing I/II phase study provides hope for patients who have failed at least one line of anti-CD20 monoclonal antibody treatment [2]

Group 1 - The core viewpoint of the news is that Yiming Biotech has made significant progress in the development of innovative drugs for autoimmune diseases, specifically with the acceptance of the clinical trial application for its dual-target antibody IMM0306S by the National Medical Products Administration (NMPA) [1] - IMM0306S is a subcutaneous formulation developed based on Yiming Biotech's core product IMM0306, which is the world's first clinical-stage dual-target specific molecule targeting CD47 and CD20, developed using the "mAb-Trap" technology platform [1] - The stock price of Yiming Biotech increased by nearly 4%, with a current trading price of 6.23 HKD and a trading volume of 3.12 million HKD [1] Group 2 - At the 67th American Society of Hematology (ASH) annual meeting, Yiming Biotech presented data from a Phase I/II clinical study of IMM0306 combined with lenalidomide for the treatment of relapsed/refractory CD20-positive follicular lymphoma, showing an objective response rate (ORR) of 91.2% and a complete response (CR) rate of 67.6% in patients who had failed at least one line of anti-CD20 monoclonal antibody treatment [2] - The safety profile of the combination therapy was reported to be manageable, with no risk of cytokine release syndrome, providing a promising new immunotherapy strategy for this currently incurable disease with limited treatment options after relapse [2]